Simultaneous Effects of Metformin and Sitagliptin on the Contents of Insulin Resistance Proteins Glucose Transporter 4 and Protein Kinase B in Diabetic Patients&#039; Adipose Tissue

Didehdar, Reza; Naghiaee, Yousof; Mohiti-Ardekani, Javad; Heiranizadeh, Naeimeh; Rahmanian, Masaoud

doi:10.18502/ijdo.v13i2.6479

Volume 13, Issue 2 (volume 13, number 2 2021) IJDO 2021, 13(2): 102-108 | Back to browse issues page

‎ 10.18502/ijdo.v13i2.6479

Mendeley

Zotero

RefWorks

Didehdar R, Naghiaee Y, Mohiti-Ardekani J, Heiranizadeh N, Rahmanian M. Simultaneous Effects of Metformin and Sitagliptin on the Contents of Insulin Resistance Proteins Glucose Transporter 4 and Protein Kinase B in Diabetic Patients' Adipose Tissue. IJDO 2021; 13 (2) :102-108
URL: http://ijdo.ssu.ac.ir/article-1-632-en.html

Simultaneous Effects of Metformin and Sitagliptin on the Contents of Insulin Resistance Proteins Glucose Transporter 4 and Protein Kinase B in Diabetic Patients' Adipose Tissue

Reza Didehdar ^*

, Yousof Naghiaee

, Javad Mohiti-Ardekani

, Naeimeh Heiranizadeh

, Masaoud Rahmanian

Department of Biochemistry and Molecular Biology, Faculty of Medicine, International Campus Of Shahid Saduoghi University of Medical Sciences, Yazd, Iran. Department of Biochemistry, Faculty of Medicine, Zabol University of Medical Sciences, Zabol, Iran.

Abstract: (972 Views)

Objective: Obesity is a factor in the development of insulin resistance and type 2 diabetes. Obesity contributes a wide variety of metabolic changes such as insulin resistance. The insulin signal mechanism to intra-cells occurs in insulin resistance, primarily in adipose tissue cells, which can be appropriate targets for therapeutic approaches by recognizing the proteins in this pathway. The study aimed to evaluate the simultaneous impact of metformin and sitagliptin on the expression of protein levels involved in insulin resistance Protein Kinase B (Akt) and Glucose Transporter 4 (GLUT4) in diabetic adipose tissue.
Materials and Methods: In order to evaluate the content of proteins involved in insulin resistance Akt and GLUT4 in adipose tissue of diabetic patients with the use of SDS-PAGE and western blot analyses, we studied 6 persons of type 2 diabetic patients who obtained 3 months of care with simultaneous metformin and sitagliptin, 4 persons returned from them after treatment and 8 persons as a stable case (control group).
Results: There was an increase in glucose intake and a decrease in serum glucose levels (P-value= 0.025) and no decrease in insulin resistance (P-value= 0.6) following simultaneous metformin and sitagliptin therapy, but no improvement in serum insulin levels (P-value=1.01). Increases in the content of Akt protein (P-value= 0.682) and GLUT4 protein (P-value= 0.851) involved in insulin resistance in diabetic patients' adipose tissue, were not observed.
Conclusion: Simultaneous treatment with metformin and sitagliptin had no effect on insulin resistance proteins Akt and GLUT4 in type 2 diabetic adipose tissue.

Keywords: Insulin Resistance, Metformin, Sitagliptin, Type 2 diabetes, Glucose transporter 4, Protein Kinase B

Full-Text [PDF 578 kb] (425 Downloads)

Type of Study: Research | Subject: Special
Received: 2021/06/16 | Accepted: 2021/06/20 | Published: 2021/06/20

References

1. Zhang C, Klett EL, Coleman RA. Lipid signals and insulin resistance. Clinical lipidology. 2013;8(6):659-67. [DOI:10.2217/clp.13.67]

2. Guo S. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models to disease mechanisms. The Journal of endocrinology. 2014;220(2):1-23. https://doi.org/10.1530/JOE-13-0327 [DOI:10.1530/JOE-13-0584]

3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. 2015;38(1):140-9. [DOI:10.2337/dc14-2441]

4. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Current medical research and opinion. 2008;24(2):489-96. [DOI:10.1185/030079908X261069]

5. Souza-Mello V, Gregorio BM, Cardoso-de-Lemos FS, de Carvalho L, Aguila MB, Mandarim-de-Lacerda CA. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clinical science. 2010;119(6):239-50. [DOI:10.1042/CS20100061]

6. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes care. 2004;27(6):1487-95. [DOI:10.2337/diacare.27.6.1487]

7. Matthews DR, Wallace TM. Children with type 2 diabetes: the risks of complications. Hormone Research in Paediatrics. 2002;57(1):34-9. [DOI:10.1159/000053310]

8. Carswell KA, Lee MJ, Fried SK. Culture of isolated human adipocytes and isolated adipose tissue. InHuman cell culture protocols 2012 (203-14). Humana Press. [DOI:10.1007/978-1-61779-367-7_14]

9. Ahrari I, Zarandi NP, Maharlooei MK, Monabati A, Attari A, Ahrari S. Adipose tissue derived multipotent mesenchymal stromal cells can be isolated using serum-free media. Iranian Red Crescent Medical Journal. 2013;15(4):324. [DOI:10.5812/ircmj.4506]

10. Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, Miura A, et al. Activation of protein kinase C-ζ by insulin and phosphatidylinositol-3, 4, 5-(PO4) 3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes. 2003;52(8):1926-34. [DOI:10.2337/diabetes.52.8.1926]

11. Luna V, Casauban L, Sajan MP, Gomez-Daspet J, Powe JL, Miura A, et al. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3, 4, 5-(PO 4) 3 in muscle of diabetic subjects. Diabetologia. 2006;49(2):375-82. [DOI:10.1007/s00125-005-0112-4]

12. Temofonte N, Sajan MP, Nimal S, Pastoor T, Fumero C, Casaubon L, et al. Combined thiazolidinedione- metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle. Diabetologia. 2009;52(1):60-4. [DOI:10.1007/s00125-008-1180-z]

13. Williams‐Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2010;12(5):442-51. [DOI:10.1111/j.1463-1326.2010.01204.x]

14. Farese RV, Sajan MP, Yang H, Li P, Mastorides S, Gower WR, et al. Muscle-specific knockout of PKC-λ impairs glucose transport and induces metabolic and diabetic syndromes. The Journal of Clinical Investigation. 2007;117(8):2289-301. [DOI:10.1172/JCI31408]